MicroRNA-27a Regulates Lipid Metabolism and Inhibits Hepatitis C Virus Replication in Human Hepatoma Cells

Takayoshi Shirasaki,[a,b] Masao Honda,[a,b] Tetsuro Shimakami,[a] Rika Horii,[a] Taro Yamashita,[a] Yoshio Sakai,[a] Akito Sakai,[a] Hikari Okada,[a] Risa Watanabe,[b] Seishi Murakami,[a] MinKyung Yi,[c] Stanley M. Lemon,[d] Shuichi Kaneko[a]

Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan[a]; Department of Advanced Medical Technology, Kanazawa University Graduate School of Health Medicine, Kanazawa, Japan[b]; Human Center for Hepatitis Research, Institute for Human Infections and Immunity, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA[c]; Division of Infectious Diseases, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA[d]

The replication and infectivity of the lipotropic hepatitis C virus (HCV) are regulated by cellular lipid status. Among differentially expressed microRNAs (miRNAs), we found that miR-27a was preferentially expressed in HCV-infected liver over hepatitis B virus (HBV)-infected liver. Gene expression profiling of Huh-7.5 cells showed that miR-27a regulates lipid metabolism by targeting the lipid synthetic transcription factor RXRα and the lipid transporter ATP-binding cassette subfamily A member 1. In addition, miR-27a repressed the expression of many lipid metabolism-related genes, including *FASN*, *SREBP1*, *SREBP2*, *PPARα*, and *PPARγ*, as well as *ApoA1*, *ApoB100*, and *ApoE3*, which are essential for the production of infectious viral particles. miR-27a repression increased the cellular lipid content, decreased the buoyant density of HCV particles from 1.13 to 1.08 g/cm^3, and increased viral replication and infectivity. miR-27a overexpression substantially decreased viral infectivity. Furthermore, miR-27a enhanced *in vitro* interferon (IFN) signaling, and patients who expressed high levels of miR-27a in the liver showed a more favorable response to pegylated IFN and ribavirin combination therapy. Interestingly, the expression of miR-27a was upregulated by HCV infection and lipid overload through the adipocyte differentiation transcription factor C/EBPα. In turn, upregulated miR-27a repressed HCV infection and lipid storage in cells. Thus, this negative feedback mechanism might contribute to the maintenance of a low viral load and would be beneficial to the virus by allowing it to escape host immune surveillance and establish a persistent chronic HCV infection.

MicroRNA (miRNA) is a small, endogenous, single-stranded, noncoding RNA consisting of 20 to 25 bases that regulates gene expression. It plays an important role in various biological processes, including organ development, differentiation, and cellular death and proliferation, and is also involved in infection and diseases such as cancer (1).

Previously, we examined miRNA expression in hepatocellular carcinoma (HCC) and noncancerous background liver tissue infected with hepatitis B virus (HBV) and HCV (2). We showed that some miRNAs were differentially expressed according to HBV or HCV infection but not according to the presence of HCC. These infection-specific miRNAs were believed to regulate HBV or HCV replication; however, their functional role has not been elucidated.

HCV is described as a lipotropic virus because of its association with serum lipoprotein (3–5). It utilizes the low-density lipoprotein (LDL) receptor for cellular entry (6–8) and forms replication complexes on lipid rafts (9). The HCV core protein surrounds and binds lipid droplets (LDs) and nonstructural proteins on the endoplasmic reticulum (ER) membrane, which is essential for particle formation (10). Moreover, HCV cellular secretion is linked to very LDL (VLDL) secretion (11). In liver tissue histology, steatosis is often observed in chronic hepatitis C (CH-C) and is closely related to resistance to interferon (IFN) treatment (12, 13). Thus, lipids play important roles in HCV replication and CH-C pathogenesis.

Several miRNAs, such as miR-122 (14), miR-199a (15), miR-196 (16), miR-29 (17), Let-7b (18), and miR-130a (19), reportedly regulate HCV replication; however, miRNAs that regulate lipid metabolism and HCV replication have not been reported so far.

Previously, we reported that 19 miRNAs were differentially expressed in HBV- and HCV-infected livers (2). In the present study, we evaluated the functional relevance of miR-27a in HCV replication by using the human hepatoma cell line Huh-7.5. We analyzed the regulation of lipid metabolism by miR-27a in hepatocytes and revealed a unique pathophysiological relationship between lipid metabolism and HCV replication in CH-C.

MATERIALS AND METHODS

Cell line. Huh-7.5 cells (kindly provided by C. M. Rice, Rockefeller University, New York, NY) were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

HCV replication analysis. HCV replication analysis was performed by transfecting Huh-7.5 cells with JFH-1 (20), H77Sv2 Gluc2A (21), and their derivative RNA constructs. pH77Sv2 is a modification of pH77S, a plasmid containing the full-length sequence of the genotype 1a H77 HCV strain with five cell culture-adaptive mutations that promote its replication in Huh-7 hepatoma cells (21–24). pH77Sv2 Gluc2A is a related construct in which the *Gaussia* luciferase (Gluc) sequence, fused to the 2A autocatalytic protease of foot-and-mouth virus RNA, was inserted in frame between p7 and NS2 (21, 23, 25). pH77Sv2 Gluc2A (AAG) is a control plasmid that has an NS5B polymerase catalytic domain mutation.

5270 jvi.asm.org
Journal of Virology   p. 5270–5286
May 2013 Volume 87 Number 9

For RNA transfection, the cells were washed with phosphate-buffered saline (PBS) and resuspended in complete growth medium. The cells were then pelleted by centrifugation ($1,400 \times g$ for 4 min at 4°C), washed twice with ice-cold PBS, and resuspended in ice-cold PBS at a concentration of 7.5×10^6 cells/0.4 ml. The cells were mixed with 10 μg of the RNA transcripts, placed into 2-mm-gap electroporation cuvettes (BTX Genetronics, San Diego, CA), and electroporated with five pulses of 99 μs at 750 V over 1.1 s in an ECM 830 (BTX Genetronics). Following a 10-min recovery period, the cells were mixed with complete growth medium and plated.

miR-27a and anti-miR-27a transfection. Huh-7.5 cells transfected with pH77Sv2 Gluc2A RNA or pH77Sv2 Gluc2A (AAG) RNA were transfected with 50 nM synthetic miRNA (pre-miRNA) or 50 nM anti-miRNA (Ambion Inc., Austin, TX) with the siPORTTM NeoFXTM Transfection Agent (Ambion). Transfection was performed immediately by mixing the electroporated cells with the miRNA transfection reagents. Control samples were transfected with an equal concentration of a nontargeting control (pre-miRNA negative control) or inhibitor negative control (anti-miRNA negative control) to assess non-sequence-specific effects in the miRNA experiments.

Fatty acid treatment. Huh-7.5 cells transfected with HCV RNA and pre- or anti-miRNA were cultured for 24 h and then treated with the indicated concentrations of oleic acid (0 to 250 μM) (26) in the presence of 2% free fatty acid (FFA)-free bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO). The cells were harvested at 72 h posttreatment with oleic acid for quantitative real-time detection PCR (RTD-PCR), Western blotting, immunofluorescence staining, and reporter analysis. The number of viable cells was determined by an MTS assay [one-step 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay; Promega Corporation, Madison, WI]. Cellular triglyceride (TG) and cholesterol (TCHO) contents were measured with TG Test Wako and Cholesterol Test Wako kits (Wako, Osaka, Japan) according to the manufacturer's instructions.

Equilibrium ultracentrifugation of JFH-1 particles in isopycnic iodixanol gradients. Filtered supernatant fluids collected from JFH-1 RNA- and pre-miRNA- or anti-miRNA-transfected cell cultures were concentrated 30-fold with a Centricon PBHK Centrifugal Plus-20 filter unit with an Ultracel PL membrane (100-kDa exclusion; Merck Millipore, Billerica, MA) and then layered on top of a preformed continuous 10 to 40% iodixanol (OptiPrep; Sigma-Aldrich) gradient in Hanks' balanced salt solution (Invitrogen, Carlsbad, CA) as described previously (24). The gradients were centrifuged in an SW41 rotor (Beckman Coulter Inc., Brea, CA) at 35,000 rpm for 16 h at 4°C, and the fractions (500 μl each) were collected from the top of the tube. The density of each fraction was determined with a digital refractometer (Atago, Tokyo, Japan).

Infectivity assays. Huh-7.5 cells were seeded at 5.0×10^4/well in 48-well plates 24 h before inoculation with 100 μl of the gradient fractions. The cells were tested for the presence of intracellular core antigen by immunofluorescence 72 h later, as described below. Clusters of infected cells that stained for the core antigen were considered to constitute a single infectious focus, and virus titers were calculated accordingly in terms of numbers of focus-forming units (FFU)/ml.

Western blotting and immunofluorescence staining. Western blotting was performed as described previously (27). The cells were washed in PBS and lysed in radioimmunoprecipitation assay buffer containing Complete protease inhibitor cocktail and PhosSTOP (Roche Applied Science, Indianapolis, IN). The membranes were blocked in Blocking One or Blocking One-P solution (Nacalai Tesque, Kyoto, Japan), and the expression of HCV core protein, retinoid X receptor alpha (RXRα), sterol regulatory element-binding protein (SREBP1), ATP-binding cassette subfamily A member 1 (ABCA1), ApoE3, ApoB100, fatty acid synthase (FASN), peroxisome proliferator-activated receptor α (PPARα), ApoA1, phospho-PKR-like ER kinase (phospho-PERK), PERK, phospho-eIF2α, eIF2α, BIP, phospho-STAT1, and β-actin was evaluated with mouse anti-

core (Thermo Fisher Scientific Inc., Rockford, IL), rabbit anti-RXRα, rabbit anti-SREBP1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), mouse anti-ABCA1 (Abcam, Cambridge, MA), goat anti-ApoE3, goat anti-ApoB100 (R&D Systems Inc., Minneapolis, MN), rabbit anti-FASN, rabbit anti-PPARα, mouse anti-ApoA1, rabbit anti-phospho-PERK, rabbit anti-PERK, rabbit anti-phospho-eIF2α, rabbit anti-eIF2α, rabbit anti-BIP, rabbit anti-phospho-STAT1, and rabbit anti-β-actin antibodies (Cell Signaling Technology Inc., Danvers, MA), respectively.

For immunofluorescence staining, the cells were washed twice with PBS and fixed in 4% paraformaldehyde for 15 min at room temperature. After washing again with PBS, the cells were permeabilized with 0.05% Triton X-100 in PBS for 15 min at room temperature. They were then incubated in a blocking solution (10% FBS and 5% BSA in PBS) for 30 min and with the anti-core monoclonal antibodies. The fluorescent secondary antibodies were Alexa 568-conjugated anti-mouse IgG antibodies (Invitrogen). Nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI), and LDs were visualized with boron-dipyrromethene (BODIPY) 493/503 (Invitrogen). Imaging was performed with a CSU-X1 confocal microscope (Yokogawa Electric Corporation, Tokyo, Japan).

Quantitative RTD-PCR. Total RNA was isolated with a GenElute Mammalian Total RNA Miniprep kit (Sigma-Aldrich), and cDNA was synthesized with a high-capacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA). The primer pairs and probes for C/EBPα, ABCA1, PPARγ, SREBF1, SREBF2, FASN, 2′-5′-oligoadenylate synthetase 2 (OAS2), and β-actin were obtained from the TaqMan assay reagent library. HCV RNA was detected as described previously (28). HCV RNA was isolated from viral particles with a QIAamp viral RNA kit (Qiagen, Inc., Valencia, CA) in accordance with the manufacturer's instructions. Total RNA containing miRNA was isolated according to the protocol of the mirVana miRNA isolation kit (Ambion). For the enrichment of mature miRNA, argonaute 2 (Ago2)-binding miRNA was immunoprecipitated with an anti-Ago2 monoclonal antibody (Wako) and mature miRNA was eluted from the precipitant with a microRNA isolation kit, Human Ago2 (Wako). cDNA was prepared via reverse transcription with 10 ng of isolated total RNA and 3 μl of each reverse transcription primer with specific loop structures. Reverse transcription was performed with a TaqMan MicroRNA reverse transcription kit (Applied Biosystems) according to the manufacturer's protocol. RTD-PCR was performed with the 7500 Real Time PCR system (Applied Biosystems) according to the manufacturer's instructions. The primer pairs and probes for miR-let7a, miR-34c, miR-142-5p, miR-27a, miR-23a, and RNU6B were obtained from the TaqMan assay reagent library.

3′ UTR luciferase reporter assays. The miRNA expression reporter vector pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega Corporation) was used to validate the RXRα and ABCA1 3′ untranslated regions (UTRs) as miRNA binding sites. cDNA fragments corresponding to the entire 3′ UTR of human RXRα and human ABCA1 were amplified with the Access RT-PCR system (Promega Corporation) from total RNA extracted from Huh-7.5 cells. The PCR products were cloned into the designated multiple cloning site downstream of the luciferase open reading frame between the SacI and XhoI restriction sites of the pCR2.1-TOPO vector (Invitrogen). Point mutations in the seed region of the predicted miR-27a sites within the 3′ UTR of human RXRα and human ABCA1 were generated with a QuikChange Multi site-directed mutagenesis kit (Agilent Technologies Inc., Santa Clara, CA) according to the manufacturer's protocol. All constructs were confirmed by sequencing.

Huh-7.5 cells were grown to 70% confluence in 24-well plates in complete DMEM. The cells were cotransfected with 200 ng of the indicated 3′ UTR luciferase reporter vector and 50 nM synthetic miRNA (pre-miRNA) or 50 nM anti-miRNA (Ambion) in a final volume of 0.5 ml with Lipofectamine 2000 (Invitrogen). At 24 h posttransfection, firefly and *Renilla* luciferase activities were measured consecutively with the Dual-Luciferase Reporter Assay system (Promega Corporation).

FIG 1 miR-27a has a negative effect on HCV replication and infectivity. Huh-7.5 cells were transfected with JFH-1 RNA and pre- or anti-miRNA. Expression was quantified at 72 h posttransfection. (A) Inhibition efficiency of miRNAs by anti-miRNAs (RTD-PCR, $n = 6$). (B) Effects of anti-miRNAs on HCV replication (RTD-PCR, $n = 6$). (C) Detection of whole miR-27a and Ago2-binding miR-27a in Huh-7.5 cells. At 72 h posttransfection, cells were harvested and Ago2-binding miRNA was purified as described in Materials and Methods. White bars indicate total miR-27a levels, and black bars indicate Ago2-binding miR-27a levels (RTD-PCR, $n = 6$). (D) Effects of pre- or anti-miR-27a on cell viability (left) and HCV replication (right). Cell viability (%) was assessed by the MTS assay ($n = 6$). (E) Effects of pre- or anti-miR-27a on HCV core protein levels by Western blotting. (F) Effects of pre- or anti-miR-27a on HCV infection. Huh-7.5 cells were infected with HCVcc derived from Huh-7.5 cells transfected with pre- or anti-miR-27a and JFH-1 RNA. HCV RNA was quantified at 72 h postinfection by RTD-PCR ($n = 6$). All experiments were performed in duplicate and repeated three times. Values are means ± standard errors. *, $P < 0.01$; **, $P < 0.005$.

Promoter analysis. DNA fragments from -400 to $+36$ bp and from -700 to $+36$ bp relative to the transcription initiation site of pri-miR-23a~27a~24-2 were inserted into pGL3-Basic (Promega Corporation) at the MluI and XhoI sites. Point mutations in the seed region of predicted C/EBPα binding sites were generated with a QuikChange Multi site-directed mutagenesis kit (Agilent Technologies) according to the manufacturer's protocol. All constructs were confirmed by sequencing.

Huh-7.5 cells transfected with HCV RNA were cultured for 24 h in 24-well plates, and then 200 ng of the plasmids was cotransfected with 2 ng of the *Renilla* luciferase expression vector (pSV40-Renilla) with FuGENE6 Transfection Reagent (Roche Applied Science). After 24 h, the cells were treated with oleic acid in the presence of 2% FFA-free BSA (Sigma-Aldrich). At 48 h posttreatment, a luciferase assay was carried out with the Dual-Luciferase Reporter Assay system (Promega Corporation) according to the manufacturer's instructions.

For tunicamycin treatment, the plasmids (200 ng) were cotransfected with 2 ng pSV40-Renilla with FuGENE6 (Roche Applied Science) into Huh-7.5 cells grown in the wells of 24-well plates. After 24 h, the cells were treated for a further 24 h with the indicated concentrations of tunicamycin and a luciferase assay was carried out as described above.

RNA interference. A small interfering RNA (siRNA) specific to ABCA1 and a control siRNA were obtained from Thermo Fisher Scientific. Transfection was performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.

IFN treatment. Huh-7.5 cells transfected with HCV RNA and pre- or anti-miRNA were treated with oleic acid as described above. At 48 h later,

the cells were treated with the indicated number of international units of IFN-α for 24 h.

Affymetrix GeneChip analysis. Aliquots of total RNA (50 ng) isolated from the cells were subjected to amplification with the WT-Ovation Pico RNA Amplification system (NuGen, San Carlos, CA) according to the manufacturer's instructions. The Affymetrix Human U133 Plus 2.0 microarray chip containing 54,675 probes has been described previously (29).

Statistical analysis. Results are expressed as mean values ± standard errors. At least six samples were tested in each assay. Significance was tested by one-way analysis of variance with Bonferroni methods, and differences were considered statistically significant at P values of <0.01 (*, $P < 0.01$; **, $P < 0.005$).

Microarray accession number. The expression data determined in this study were deposited in the Gene Expression Omnibus database (NCBI) under accession number GSE41737.

RESULTS

Functional relevance of the upregulated miRNAs in HCV-infected livers. Previously, 19 miRNAs were shown to be differentially expressed in HBV- and HCV-infected livers (2). Of these, 6 miRNAs were upregulated and 13 were downregulated. In this study, we focused on the upregulated miRNAs, as they might play a positive role in HCV replication. Anti-miRNAs and the control miRNA were transfected into Huh-7.5 cells following JFH-1 RNA

TABLE 1 Gene categories and names of differentially expressed genes regulated by miR-27a in Huh-7.5 cells

Protein function and name	Gene	Affy ID[a]	GB acc. no.[b]	Fold change Pre-miR-27a/ miR-control	Anti-miR-27a/ anti-miR-control	Pre-miR-27a/ anti-miR-27a
Cytoskeleton remodeling and Wnt signaling						
Collagen, type IV, alpha 6	COL4A6	211473_s_at	U04845	0.85	2.19	2.58
Fibronectin 1	FN1	214702_at	AJ276395	0.57	1.14	2.02
Filamin A, alpha	FLNA	214752_x_at	AI625550	0.64	1.68	2.61
LIM domain kinase 1	LIMK1	204357_s_at	NM_002314	0.67	1.63	2.43
p21/Cdc42/Rac1-activated kinase 1	PAK1	230100_x_at	AU147145	0.63	1.58	2.53
Breast cancer anti-estrogen resistance 1	BCAR1	232442_at	AU147442	0.96	1.94	2.01
Frizzled homolog 3 (Drosophila)	FZD3	219683_at	NM_017412	0.51	1.30	2.55
Laminin, alpha 4	LAMA4	210990_s_at	U77706	0.63	1.26	2.00
Regulation of lipid metabolism						
CREB binding protein (Rubinstein-Taybi syndrome)	CREBBP	235858_at	BF507909	0.54	1.50	2.76
NF-Y	NF-Y	228431_at	AL137443	0.41	1.44	3.50
Sterol regulatory element binding transcription factor 2	SREBF2	242748_at	AA112403	0.47	1.11	2.35
Membrane-bound transcription factor peptidase, site 2	MBTPS2	1554604_at	BC036465	0.50	1.21	2.39
Adenosine A2A receptor signaling						
Mitogen-activated protein kinase kinase 7	MAP2K7	226053_at	AI090153	0.90	2.07	2.31
Par-6 partitioning defective 6 homolog beta	PARD6B	235165_at	AW151704	0.56	1.35	2.43
Rap guanine nucleotide exchange factor (GEF) 2	RAPGEF2	238176_at	T86196	0.46	1.36	2.98
Ribosomal protein S6 kinase, 90kDa, polypeptide 2	RPS6KA2	204906_at	BC002363	0.61	1.72	2.83
p53 regulation						
MDM2	MDM2	237891_at	AI274906	0.41	1.27	3.07
Ubiquitin B	UBB	217144_at	X04801	0.58	1.89	3.24
Promyelocytic leukemia	PML	235508_at	AW291023	0.52	1.45	2.80
SMT3 suppressor of mif two 3 homolog 1	SUMO1	208762_at	U83117	0.55	1.23	2.22
IL-8 in angiogenesis						
B-cell CLL/lymphoma 10	BCL10	1557257_at	AA994334	0.59	1.23	2.08
Janus kinase 2	JAK2	205841_at	NM_004972	0.77	1.71	2.23
Sphingosine-1-phosphate receptor 1						
G protein, alpha inhibiting activity polypeptide 2	GNAI2	201040_at	NM_002070	0.69	1.49	2.15
G protein, beta polypeptide 4	GNB4	223487_x_at	AW504458	0.86	1.78	2.06
Mitogen-activated protein kinase 1	MAPK1	1552263_at	NM_138957	0.87	1.93	2.22
GRB2-associated binding protein 1	GAB1	226002_at	AK022142	0.66	1.40	2.11

[a] Affy ID, Affymetrix identification number.
[b] GB acc. no., GenBank accession number.

transfection. The efficiency with which these anti-miRNAs inhibit the miRNAs is shown in Fig. 1A. Unexpectedly, inhibition of these miRNAs either had no effect or increased HCV replication in the cases of anti-miR-23a and anti-miR-27a (Fig. 1B).

To investigate the functional relevance of miR-27a in HCV replication in more detail, we evaluated JFH-1 replication in Huh-7.5 cells in which miR-27a was inhibited or overexpressed. The efficacy of miR-27a overexpression is shown in Fig. 1C. Although ectopically introduced pre-miR-27a increased miR-27a levels by approximately 30-fold, the levels of endogenous active Ago2 bound to miR-27a in RNA-induced silencing complexes increased by approximately 5-fold. The RNA and core protein levels of JFH-1 in Huh-7.5 cells decreased to 65% and 40%, respectively, following miR-27a overexpression. In contrast, the RNA and core protein levels of JFH-1 increased by 3- and 1.9-fold, respectively, following miR-27a inhibition (Fig. 1D and E). There was no significant difference in cell viability following miR-27a overexpression or inhibition (Fig. 1D). Furthermore, the rate of Huh-7.5 cell

infection by JFH-1 decreased to 35% after the overexpression of miR-27a but increased 4-fold after miR-27a inhibition (Fig. 1F). Thus, miR-27a negatively regulates HCV replication and infection.

miR-27a targets the signaling pathways of cytoskeleton remodeling and lipid metabolism in Huh-7.5 cells. We next examined which signaling pathways were modulated by miR-27a. TargetScan (http://www.targetscan.org/) predicts biological targets of miRNAs by searching for the presence of conserved 8- and 7-mer sites that match the seed region of each miRNA (30). A TargetScan (release 5.2) for miR-27a predicted 921 candidate target genes, and functional gene ontology enrichment analysis of these genes by MetaCore (Thomson Reuters, New York, NY) showed that miR-27a could target the cytoskeleton remodeling and lipid metabolism signaling pathways (data not shown).

To examine whether these signaling pathways were regulated by miR-27a, gene expression profiling was carried out with Huh-7.5 cells in which miR-27a was over- or underexpressed. Transfection of cells with pre-miR-27a and pre-miR-

FIG 2 Changes in the lipid contents of Huh-7.5 cells and culture medium caused by pre- and anti-miR-27a. Huh-7.5 cells were transfected with replication-competent HCV RNA (H77Sv2 Gluc2A RNA [+HCV]) or replication-incompetent HCV RNA [H77Sv2 Gluc2A (AAG) (+AAG)] together with pre- or anti-miR-27a. At 24 h posttransfection, increasing amounts of oleic acid (0 to 250 μM) were added to the culture medium, and at 72 h after oleic acid treatment, TG and TCHO levels were measured in the cells and medium. Panels: A, TG in cells; B, TCHO in cells; C, TG in medium; D, TCHO in medium; E, TG and TCHO in cells and medium; A to D, +H77Sv2 Gluc2A (+HCV); E, +H77Sv2 Gluc2A (AAG) (+AAG). Lipid concentration was compared with that of miR-control and pre- or anti-miRNA ($n = 6$). All experiments were performed in duplicate and repeated three times. Values are means ± standard errors. *, $P < 0.01$; **, $P < 0.005$.

control or with anti-miR-27a and anti-miR-control enabled the identification of down- and upregulated genes, respectively. A total of 870 genes were selected with a >2-fold anti-miR-27a/pre-miR-27a expression ratio. Pathway analysis of these genes with MetaCore revealed that they are involved in cytoskeleton remodeling signaling, including that of COL4A6, FN 1, and PAK1; lipid metabolism signaling, including that of CREBBP and SREBF2; A2A receptor signaling, including that of RAPGEF2; and p53 regulation signaling, including that of MDM2. These genes were repressed by miR-27a in Huh-7.5 cells (Table 1).

miR-27a reduces TG and TCHO levels in cells and culture medium. Pathway analysis of the gene expression profile regu-

lated by miR-27a in Huh-7.5 cells revealed the presence of many genes involved in lipid metabolism-related signaling pathways. To examine the functional relevance of miR-27a in lipid metabolism, we measured the cellular levels of TG and TCHO in Huh-7.5 cells in which miR-27a was inhibited or overexpressed, respectively. As shown in Fig. 2A and B, TG and TCHO levels in Huh-7.5 cells transfected with miR-control were increased in a dose-dependent manner following the addition of oleic acid (0 to 250 μM). Pre-miR-27a repressed this increase, while anti-miR-27a significantly accelerated it. Similarly, pre-miR-27a repressed the increase in TG and TCHO in the culture medium, while anti-miR-27a significantly accelerated it (Fig. 2C and D).

Similar results were obtained with both HCV-replicating cells

FIG 3 Changes in HCV replication in Huh-7.5 cells caused by pre- and anti-miR-27. Huh-7.5 cells were transfected with H77Sv2 Gluc2A RNA or H77Sv2 Gluc2A (AAG) RNA and pre- or anti-miR-27a. At 24 h posttransfection, increasing amounts of oleic acid (0 to 250 μM) were added to the culture medium. At 72 h after oleic acid treatment, the cells were harvested. (A) Gluc activity in the medium reflecting HCV replication in cells ($n = 6$). (B) Effects of pre- or anti-miR-27 on HCV RNA levels (RTD-PCR, $n = 6$). Experiments were performed in duplicate and repeated three times. Values are means ± standard errors. *, $P < 0.01$; **, $P < 0.005$. (C) Western blotting of HCV core protein in the same experiments. (D and E) Confocal microscopy images of Huh-7.5 cells in the same experiments. D, +H77Sv2 Gluc2A (AAG); E, +H77Sv2 Gluc2A. Cells were fixed, permeabilized, and stained with an anti-HCV core protein antibody. Nuclei were labeled with DAPI. LDs were visualized with BODIPY 493/503 dye. Imaging was performed with a CSU-X1 confocal microscope.

FIG 4 Equilibrium ultracentrifugation of JFH-1 particles in isopycnic iodixanol gradients. Filtered supernatant fluids collected from JFH-1 RNA- and pre- or anti-miRNA-transfected Huh-7.5 cell cultures were concentrated and used to collect fractions (500 μl each). Black circles indicate the gradient densities of the fractions, white circles indicate the HCV RNA titers, and bars indicate HCV infectivity levels. Panels: A, cells overexpressing pre-miR-control; B, cells overexpressing pre-miR-27a; C, cells overexpressing anti-miR-control; D, cells overexpressing anti-miR-27a. Experiments were repeated twice.

(+HCV) (Fig. 2A to D) and non-HCV-replicating cells (+AAG) (Fig. 2E), although the changes in the levels of TG and TCHO in the culture medium were smaller for the non-HCV-replicating cells (+AAG) (Fig. 2E). Correlating with the lipid component findings, replication of the infectious HCV clone H77Sv2 Gluc2A (21), as determined by Gluc activity in the culture medium, and the HCV RNA titer were significantly repressed by pre-miR-27a and increased by anti-miR-27a (Fig. 3A and B). This result was also confirmed by the core protein levels determined by Western blotting (Fig. 3C).

The localization of LDs and core proteins in the cells was visualized by confocal laser microscopy with a lipotropic fluorescent dye and immunostaining of the core protein (Fig. 3E). The LD and core protein levels were substantially repressed by pre-miR-27a and greatly increased by anti-miR-27a antibody. The change in the levels of LDs caused by miR-27a was observed in both HCV-replicating cells (Fig. 3E) and non-HCV-replicating cells (Fig. 3D), although the magnitude of the change was more prominent in HCV-replicating cells.

miR-27a changes the buoyant density and infectivity of HCV particles. The culture medium of Huh-7.5 cells in which JFH-1 was replicating was fractionated by iodixanol gradient centrifugation, and the buoyant density of HCV particles was evaluated (Fig. 4). When the cells were transfected with control miRNA (pre-miR-control and anti-miR-control), the HCV

RNA titer (number of copies/ml) and infectivity (number of FFU/ml) peaked at fraction 7 (Fig. 4A and D) and the buoyant density of HCV was estimated at around 1.13 g/cm³. Transfection with pre-miR-27a did not change the buoyant density of HCV, but it reduced the HCV RNA titer to 0.25-fold of the control and HCV infectivity to 0.024-fold of the control (Fig. 4B). In contrast, transfection with anti-miR-27a reduced the buoyant density of HCV from 1.13 to 1.08 g/cm³ (Fig. 4B) and increased the HCV RNA titer to 2.1-fold of the control and infectivity to 2.5-fold of the control (Fig. 4C and D). Thus, miR-27a changed the buoyant density and infectivity of HCV.

miR-27a regulates lipid metabolism-related gene expression. The regulation of lipid metabolism-related genes by miR-27a was evaluated in Huh-7.5 cells (Fig. 5 and 6). The lipid synthesis transcription factors PPARγ, FASN, SREBP1, SREBP2, and RXRα were slightly, but significantly, induced in cells in which H77Sv2 Gluc2A replicated. The expression of lipid synthesis transcription factors was compared with that from cells carrying replication-incompetent H77Sv2 Gluc2A (AAG) (Fig. 5 and 6). Unexpectedly, lipid overload with oleic acid had no effect or rather decreased the levels of these transcription factors in non-HCV-replicating cells, probably because of negative feedback mechanisms. Conversely, in HCV-replicating cells, lipid overload with oleic acid further increased the levels of these transcription factors at both the

FIG 5 Expression of lipid metabolism-related transcription factors. Huh-7.5 cells were transfected with H77Sv2 Gluc2A RNA or H77Sv2 Gluc2A (AAG) RNA and pre- or anti-miR-27a. At 24 h posttransfection, oleic acid (100 μM) was added to the culture medium, and at 72 h after oleic acid treatment, *PPARγ*, *SREBP1*, *SREBP2*, and *FASN* expression levels were quantified by RTD-PCR (*n* = 6). Experiments were performed in duplicate and repeated three times. Values are means ± standard errors. *, *P* < 0.01; **, *P* < 0.005.

mRNA and protein levels (Fig. 5 and 6A and B). Pre-miR-27a significantly repressed the levels of these transcription factors and, conversely, anti-miR-27a significantly increased their mRNA and protein levels (Fig. 5 and 6A and B). This regulation by miR-27a was observed in both HCV-replicating and non-HCV-replicating cells, although the magnitude of the change was more prominent in HCV-replicating cells (Fig. 5).

As LDs associate with the ER-derived membrane at the site of HCV replication (10) and ER stress was recently shown to pro-

mote hepatic lipogenesis and LD formation (31), we next evaluated ER stress markers. Under HCV replication and lipid overload with oleic acid, anti-miR-27a increased the expression of the ER stress markers p-PERK, p-eIF2α, and BiP in Huh-7.5 cells. Conversely, pre-miR-27a significantly decreased the expression of these markers (Fig. 6C). Cell viability decreased after anti-miR-27a transfection and increased following pre-miR-27a treatment (Fig. 6D). Thus, miR-27a repressed the ER stress that was induced by HCV replication and lipid overload.

FIG 6 Expression of lipid metabolism-related transcription factors and ER stress-related factors. Huh-7.5 cells were transfected with H77Sv2 Gluc2A RNA or H77Sv2 Gluc2A (AAG) RNA and pre- or anti-miR-27a. At 24 h posttransfection, oleic acid (100 μM) was added to the culture medium. At 72 h after oleic acid treatment, the cells were harvested. (A) Western blotting of lipid metabolism-related transcription factors changed by HCV infection and oleic acid. Experiments were repeated three times. (B) Western blotting of lipid metabolism-related transcription factors changed by pre- or anti-miR-27a. Experiments were repeated three times. (C) Western blotting of ER stress-related transcription factors changed by pre- or anti-miR-27a. Experiments were repeated three times. (D) Cell viability in the same experiments was determined by MTS assay ($n = 9$). Experiments were performed in triplicate and repeated three times. Values are means ± standard errors. *, $P < 0.01$; **, $P < 0.005$.

miR-27a targets RXRα and the ATP-binding cassette transporter ABCA1. We next analyzed the expression of miR-27a target genes. A previous report showed that miR-27a targets RXRα in rat hepatic stellate cells (32), and we confirmed that miR-27a targets the 3′ UTR of human RXRα in Huh-7.5 cells (data not shown). Although the primary sequence of the human RXRα 3′ UTR shares approximately 60% homology with the corresponding rat sequence, the putative miR-27a binding site (ACUGUGAA) is conserved among several different species. Therefore, we constructed an expression vector containing a luciferase (Luc) reporter gene fused to the human RXRα 3′ UTR (pmirGLO-RXRα 3′ UTR) and reevaluated Luc activity (data not shown). Pre-miR-27a repressed Luc activity, while anti-miR-27a significantly increased Luc activity. The introduction of three nucleotide mutations into the conserved miR-27a binding site was shown to abolish these changes in Luc activity. These results confirmed previous findings that miR-27a targets RXRα (32). RXRα interacts with liver X receptor (LXR) and regulates many lipid

synthetic genes such as *SREBP1* and *FASN*. We found that the expression of *SREBP1*, *FASN*, and *SREBP2* was regulated by miR-27a (Fig. 6B) and confirmed that *PPARγ* was also regulated by miR-27a, as reported previously (Fig. 5) (33). In addition, *PPARα* was shown to be regulated by miR-27a (Fig. 6B).

We next evaluated the expression of lipid transporter genes. The ATP-binding cassette transporter ABCA1 is mutated in Tangier's disease (34) and plays an important role in the efflux of TCHO for high-density lipoprotein (HDL) synthesis (35). A recent report demonstrated a functional role for ABCA1 in hepatocyte TG secretion to the plasma and in the reduction of cellular TG levels (29). Here we found that pre-miR-27a significantly repressed ABCA1 and, conversely, that anti-miR-27a increased the mRNA and protein levels of ABCA1 (Fig. 7A and B). We identified two miR-27a binding sites (sites 1 and 2) in the 3′ UTR of ABCA1 (Fig. 7C) that were conserved between species (Fig. 7C). An expression vector containing the *luc* reporter gene fused to the human ABCA1 3′ UTR (wild type [WT]) was constructed, and a

FIG 7 miR-27a targets ABCA1. (A) Regulation of ABCA1 by pre-miR-27a. RTD-PCR and Western blotting of ABCA1 in Huh-7.5 cells at 72 h posttransfection with pre-miR-control and pre-miR-27a ($n = 6$). **, $P < 0.005$. (B) Regulation of ABCA1 by anti-miR-27a. RTD-PCR and Western blotting of ABCA1 in Huh-7.5 cells at 72 h posttransfection with pre-miR-control and anti-miR-27a ($n = 6$). **, $P < 0.005$. (C) Sequence alignment of the ABCA1 3′ UTR and the construction of the luciferase (Luc) expression vector fused to the ABCA1 3′ UTR. Ptr, *Pan troglodytes*; Mmu, *Mus musculus*; Rno, *Rattus norvegicus*; WT, Luc reporter vector with the WT ABCA1 3′ UTR (2186 to 2742); MT-1, Luc reporter vector with the site 1 mutation of the WT; MT-2, Luc reporter vector with the site 2 mutation of the WT; MT-1,2, Luc reporter vector with mutations at sites 1 and 2 of the WT. (D, E) Suppression (D) or induction (E) of Luc activity with the various mutations of the ABCA1 3′ UTR by pre-miR-27a. Huh-7.5 cells were transfected with pre- or anti-miR-control or pre- or anti-miR-27a, and WT, MT-1, MT-2, and MT-1,2. Luc activities were measured at 24 h posttransfection ($n = 6$). All experiments were performed in duplicate and repeated three times. Values are means ± standard errors. *, $P < 0.01$; **, $P < 0.005$.

FIG 8 Suppression of ABCA1 inhibits HCV replication and infection. Huh-7.5 cells were transfected with H77Sv2 Gluc2A RNA and siRNA to ABCA1 or control siRNA. ABCA1 expression was quantified at 72 h posttransfection by RTD-PCR ($n = 6$). (A) Knockdown efficiency of ABCA1 in Huh-7.5 cells by siRNA. (B) TG concentration in cells ($n = 6$). (C) TCHO concentrations in cells ($n = 6$). (D) HCV RNA assay by RTD-PCR ($n = 6$). (E) HCV infectivity. Huh-7.5 cells were infected with HCVcc derived from ABCA1 knockdown Huh-7.5 cells. HCV RNA was quantified at 72 h postinfection by RTD-PCR ($n = 6$). Experiments were performed in duplicate and repeated three times. Values are means ± standard errors. *, $P < 0.01$; **, $P < 0.005$. (F) Regulation of ApoA1, ApoE2, and ApoB100 by miR-27a. Experiments were performed under the same conditions as Fig. 6B and C and repeated three times.

series of mutations were introduced into the putative miR-27a binding sites (MT-1, MT-2, and MT-1,2). The Luc activity of the WT was significantly repressed by pre-miR-27a and increased by anti-miR-27a. However, there was a smaller change in Luc activity caused by pre- and anti-miR-27a in the single mutants (MT-1 and MT-2) and no change in Luc activity in the double mutant (MT-1,2) (Fig. 7D and E). These results show that miR-27a targets ABCA1 to decrease the lipid content of cells.

The functional relevance of ABCA1 in lipid metabolism and HCV replication in Huh-7.5 cells was examined by inhibiting ABCA1 with an siRNA (Fig. 8). siRNA to ABCA1 repressed the expression of ABCA1 in a dose-dependent manner (Fig. 8A). Under this condition, the cellular TG and TCHO levels decreased significantly (Fig. 8B and C) and HCV RNA levels also decreased to 57% of the control. More strikingly, HCV infectivity decreased to 12% of the control (Fig. 8D and E).

FIG 9 miR-27a is upregulated by HCV infection. (A) Kinetics of HCV replication and induction of miR-27a. Huh-7.5 cells were transfected with JFH-1 RNA or infection-incompetent JFH-1ΔE1E2 RNA (20). At 12, 24, 48, and 72 h posttransfection, HCV RNA (left) and miR-27a (right) levels were quantified by RTD-PCR (*n* = 6). (B) Induction of miR-27a and UV-irradiated HCV particles. Huh-7.5 cells were infected with infectious HCV (multiplicity of infection [MOI] of 0.2, 0.5, or 1) or UV-inactivated HCV. At 72 h postinfection, HCV RNA (left) and miR-27a (right) were quantified by RTD-PCR (*n* = 6). *, $P < 0.01$; **, $P < 0.005$; ND, not detected. (C) Induction of miR-27a and IFN-α treatment. Huh-7.5 cells were treated with different doses of IFN-α. At 24 h posttreatment, OAS2 (left) and miR-27a (right) were quantified by RTD-PCR (*n* = 6). All experiments were performed in duplicate and repeated three times. Values are means ± standard errors.

Several reports have demonstrated the importance of apolipo-proteins, including the major components of VLDL and LDL apoE3 (36) and apoB100 (11), in the production of infectious HCV particles. More recently, the functional relevance of ApoA1 in HCV replication and particle production has been reported (37). Here the expression of apoA1, apoB100, and apoE3 was repressed by pre-miR-27a and increased by anti-miR-27a, suggesting that miR-27a regulates the expression of apolipoproteins to reduce the production of infectious HCV particles (Fig. 8F).

Regulation of miR-27a expression through C/EBPα. miR-27a forms a gene cluster with miR-23a and miR-24-2, and both of these miRNAs are regulated by the same promoter (38). However, no detailed analysis of the regulation of this promoter has been

carried out. Because the expression of miR-27a was upregulated more in CH-C liver than CH-B liver, it could be speculated that HCV infection induces the expression of miR-27a. To examine this, we evaluated the expression of miR-27a during HCV infec-tion (Fig. 9). The expression of miR-27a increased, correlating with the increase in JFH-1 RNA, while infection-incompetent JFH-1ΔE1E2 did not induce miR-27a expression (Fig. 9A). In addition, UV-irradiated HCV particles did not induce miR-27a expression (Fig. 9B). However, IFN-α treatment did not induce the expression of miR-27a (Fig. 9C). Thus, HCV infection was essential for induction of miR-27a expression.

We identified a C/EBPα binding site (−614 to −606), a key regulator of adipocyte differentiation, in the promoter region of miR-27a. Interestingly, H77Sv2 Gluc2A and tunicamycin

FIG 10 miR-27a is regulated by the adipocyte differentiation factor C/EBPα. (A) Induction of miR-27a and C/EBPα expression by oleic acid and HCV replication. Huh-7.5 cells were transfected with H77Sv2 Gluc2A RNA or H77Sv2 Gluc2A (AAG) RNA. At 24 h posttransfection, oleic acid (100 μM) was added to the culture medium. At 72 h after oleic acid treatment, miR-27a (left) and C/EBPα (right) levels were quantified by RTD-PCR ($n = 6$). (B) Induction of miR-27a and C/EBPα expression by tunicamycin. Huh-7.5 cells were treated with different doses of tunicamycin. At 24 h after tunicamycin treatment, miR-27a (left) and C/EBPα (right) levels were quantified by RTD-PCR ($n = 6$). (C) miR-27a promoter luciferase constructs. pGL3-Pri-miR-23a/27a(-736WT) includes -700 to $+36$ relative to the transcription initiation site of pri-miR-23a~27a~24-2. pGL3-Pri-miR-23a/27a (-436) includes -400 to $+36$ bp relative to the transcription initiation site of pri-miR-23a~27a~24-2, which lacks the consensus C/EBPα binding site. pGL3-Pri-miR-23a/27a(-736MT) has mutations at the -736WT C/EBPα binding site. (D) miR-27a promoter activity in Huh-7.5 cells following HCV infection and oleic acid (left) or tunicamycin (right) treatment. Reporter constructs lacking the C/EBPα binding site did not respond to any of these conditions ($n = 6$). All experiments were performed in duplicate and repeated three times. Values are means ± standard errors. *, $P < 0.01$; **, $P < 0.005$.

significantly induced the expression of miR-27a and C/EBPα (Fig. 10A and B). To analyze the induction of miR-27a through C/EBPα, we constructed a Luc reporter construct that included the upstream promoter region (-736) of miR-27a [pGL3-Pri-miR-23a/27a(-736WT)] together with a short promoter construct (-436) lacking the C/EBPα binding site [pGL3-Pri-miR-23a/27a(-436)]. In addition, three nucleotide mutations were introduced into the C/EBPα consensus binding site to construct pGL3-Pri-miR-23a/27a(-736MT) (Fig. 10C). The activity of pGL3-Pri-miR-23a/27a(-736WT), but not that of pGL3-Pri-miR-23a/27a(-736MT) or pGL3-Pri-miR-23a/27a(-436), which both lack a C/EBPα binding site, was induced by HCV replication, lipid overload, and tunicamycin treatment (Fig. 10D). These results indicate that the regulation of miR-27a by HCV replication, lipid overload, and ER stress is mediated through C/EBPα.

Pre-miR-27a enhances IFN signaling through the reduction of lipid storage. Finally, we assessed whether miR-27a influences IFN signaling. IFN-α treatment stimulated IFN signaling in a dose-dependent manner by increasing p-STAT1 expression in Huh-7.5 cells (Fig. 11A). Oleic acid impaired this induction of p-STAT1, while pre-miR-27a restored the expression of p-STAT1 and anti-miR-27a impaired this induction by oleic acid. These findings were observed in both HCV-replicating and non-HCV-replicating cells (Fig. 11A).

HCV replication deduced from Gluc activity is shown in Fig. 11B. IFN sensitivity could be estimated by the relative fold changes in Gluc activity from the baseline activity (in the absence of IFN). The results demonstrated that oleic acid reduced IFN sensitivity, while pre-miR-27a increased IFN sensitivity under either condition with or without oleic acid (Fig. 11B).

These findings were further studied with clinical samples. The expression of miR-27a was evaluated in liver biopsy specimens obtained from 41 patients who received pegylated IFN (Peg-IFN) and ribavirin (RBV) combination therapy (Fig. 12A). Interestingly, the expression of miR-27a was significantly higher

A

B

○ Pre miR-control Oleic acid   0 μM
□ Pre miR-27a   Oleic acid   0 μM
● Pre miR-control Oleic acid 100 μM
■ Pre miR-27a   Oleic acid 100 μM

FIG 11 miR-27a restores IFN signaling impaired by lipid overload. (A) Induction of p-STAT1 expression by miR-27a. Huh-7.5 cells were transfected with H77Sv2 Gluc2A RNA or H77Sv2 Gluc2A (AAG) RNA and pre- or anti-miR-control or pre- or anti-miR-27a. At 24 h posttransfection, oleic acid (100 μM) was added to the culture medium. At 48 h after oleic acid treatment, the cells were treated with different doses of IFN-α. At 24 h after IFN treatment, p-STAT1 expression levels were determined by Western blotting. Experiments were repeated three times. (B) Absolute values of Gluc activity (left) and n-fold changes in Gluc activity (right) indicate IFN sensitivity ($n = 6$). Experiments were performed in duplicate and repeated three times. Values are means ± standard errors. *, $P < 0.01$; **, $P < 0.005$.

in patients with severe steatosis (grade 3 or 4) than in those with mild steatosis (grade 1 or 2) (Fig. 12B). Importantly, patients with a favorable response to treatment (sustained virological response or transient response) expressed higher miR-27a levels than patients with a poor response (nonresponse) (Fig. 12C). Although there was no significant difference in miR-27a expression according to the interleukin-28B (IL-28B) genotype (Fig. 12D and E), 17 patients had a treatment-resistant IL-28 genotype (TG at rs8099917) (39–41) and 6 of these with a favorable response to treatment expressed significantly higher miR-27a levels than the 11 with a poor response

(Fig. 12E). These data suggest that miR-27a enhances IFN signaling and increases the response to IFN treatment.

DISCUSSION

Previously, we examined miRNA expression in HCC and noncancerous background liver tissue infected with HBV and HCV and showed the presence of infection-specific miRNAs that were differentially expressed according to HBV or HCV infection, but not according to the presence of HCC (2). In this study, we pursued the functional analysis of these miRNAs. Among 19 infection-specific miRNAs, we first focused on 6 that were upregulated by

FIG 12 Expression of miR-27a in clinical samples. (A) Clinical characteristics of 41 patients who received Peg-IFN and RBV combination therapy. M:F, male/female ratio; SVR, sustained virological response; TR, transient response; NR, nonresponse; SNP, single nucleotide polymorphism. (B) Significant upregulation of miR-27a expression in the livers of patients with severe steatosis. Steatosis grades 1 and 2, $n = 19$; steatosis grades 3 and 4, $n = 22$. (C) Significant upregulation of miR-27a expression in the livers of patients with a favorable response to treatment (SVR or TR). Nonresponders; $n = 15$; responders, $n = 26$. (D) No significant difference in miR-27a expression between nonresponders and responders of the IL-28B major genotype (treatment-sensitive genotype) was observed. Nonresponders, $n = 3$; responders, $n = 21$. N.S., not significant. (E) Significant upregulation of liver miR-27a was observed in responders of the IL-28B minor genotype (treatment-resistant genotype). Nonresponders, $n = 11$; responders, $n = 6$.

HCV infection, as they were expected to have a positive role in HCV replication. However, inhibition experiments with a series of specific anti-miRNAs showed an unexpected increased in HCV replication. Closer examination clarified that miR-27a had a negative effect on HCV replication. Interestingly, profiling of gene expression in Huh-7.5 cells in which miR-27a was inhibited or overexpressed showed that miR-27a could target lipid metabolism signaling pathways. In support of these findings, the lipid content (TG and TCHO) of Huh-7.5 cells was significantly increased by anti-miR-27a and repressed by pre-miR-27a (Fig. 2 and 3). More importantly, miR-27a was involved in HCV particle formation, as demonstrated by iodixanol gradient centrifugation (Fig. 4). Anti-miR-27a reduced the buoyant density of HCV particles and increased HCV replication and infectivity, while pre-miR-27a decreased HCV replication and dramatically repressed HCV infectivity. In the buoyant-density experiment, the infectious HCV peaks were identical to the RNA peak and the lower infectious virus peak was not observed. We cannot explain this discrep-

ancy from other studies; however, the method used to purify the virus particles could be one reason.

miR-27a regulated many lipid metabolism-related transcription factors, such as RXRα, PPARα, PPARγ, FASN, SREBP1, and SREBP2 (Fig. 5 and 6). We also confirmed that miR-27a targets RXRα in human Huh-7.5 cells, which is concordant with a previous study showing that miR-27a targets RXRα in rat hepatic stellate cells (32). Moreover, we newly demonstrated that the gene for the lipid transporter ABCA1 is a target of miR-27a. ABCA1 mediates the efflux of TCHO and phospholipids to the lipid-poor apolipoproteins ApoA1 and ApoE, which then form nascent HDLs (34, 35). It also mediates the transport of lipids between the Golgi apparatus and the cell membrane. Recently, the knockdown of ABCA1 in rat hepatoma cells increased TG secretion to the culture medium and decreased the cellular levels of FFA (29), while liver-specific ABCA1 knockout mice fed a high-fat diet showed increased plasma TG concentrations and decreased TG and TCHO contents in the liver (42). Thus, ABCA1 regulates the lipid content

of hepatocytes, as well as HDL synthesis. In this study, we confirmed that the repression of ABCA1 decreased cellular TG and TCHO levels in Huh-7.5 cells and, importantly, decreased HCV replication and strikingly repressed HCV infection (Fig. 8).

LXR/RXRα was previously shown to activate the ABCA1 promoter (34), but we clearly demonstrated here that miR-27a directly targets ABCA1. Pre-miR-27a repressed the Luc activity of a reporter construct fused with the ABCA1 3′ UTR, while anti-miR-27a increased it. We also found that miR-27a regulates the expression of ABCA1 in a 3′ UTR sequence-specific manner, as a series of mutations introduced into putative miR-27a binding sites abrogated its regulation (Fig. 7). In addition to these findings, we showed that miR-27a repressed the expression of the apolipoproteins ApoA1, ApoB100, and ApoE3, which were recently shown to play important roles in the production and formation of infectious HCV particles (Fig. 8) (11, 36, 37). Thus, miR-27a may regulate lipid metabolism by reducing lipid synthesis and increasing lipid secretion from cells.

As the expression of miR-27a was upregulated more in CH-C liver than in CH-B liver, it is speculated that miR-27a expression is induced by HCV infection. Indeed, we clearly demonstrated that miR-27a expression was induced by HCV infection, lipid overload, and tunicamycin-induced ER stress (Fig. 9). Furthermore, the adipocyte differentiation-related transcription factor C/EBPα was involved in this regulation. A central role for C/EBPα in the development of adipose tissue has been suggested, as it was found to be sufficient to trigger the differentiation of preadipocytes into mature adipocytes (43). Thus, HCV infection might trigger lipogenesis in hepatocytes by inducing C/EBPα, as shown in this study. Conversely, the induction of C/EBPα expression by miR-27a had a negative effect on lipogenesis and HCV replication. Therefore, miR-27a might play a negative feedback role in HCV infection-induced lipid storage in hepatocytes. Moreover, HCV replication might be hampered by HCV-induced miR-27a, which would partially explain the low HCV titer in CH-C liver.

Besides the anti-HCV effect of miR-27a observed in this study, an antivirus effect against murine cytomegalovirus (MCMV) infection was observed previously (44, 45). MCMV replication was initiated by miR-27a degradation from a viral transcript, while miR-27a had a negative effect on MCMV replication. It was also reported that miR-27a was the target of *Herpesvirus saimiri* U-rich RNAs and was downregulated in transformed T lymphocytes (46). Therefore, the functional relevance of miR-27a in transformed T cells should be explored in a future study. In this study, miR-27a was upregulated by HCV infection, which is in sharp contrast to MCMV and *H. saimiri* infection. Therefore, the differences in antiviral action and host cell interactions also need to be explored further.

Our assessment of miR-27a expression in patients receiving Peg-IFN and RBV combination therapy showed that those with high miR-27a levels had a more favorable treatment response (Fig. 12). Moreover, miR-27a significantly enhanced IFN signaling (Fig. 11), suggesting that it might have therapeutic benefits in combination with IFN therapy, especially in patients with the IFN-resistant IL-28B genotype, who show a more severe steatosis than those with the IFN-sensitive IL-28B genotype (39–41). Further studies should be performed to confirm these findings with more clinical samples.

Although miR-27a has been shown to be upregulated in cancers of the breast, kidney, ovary, and gastric region, its downregulation has been reported in colorectal cancer, malignant melanoma, oral squamous cell carcinoma, and acute promyelocytic leukemia (47). However, its importance in HCC remains controversial, with one report observing its upregulation compared with the level in normal liver tissue (48), while another showed lower miR-27a expression in HCC than in paired nontumor tissues (49). Moreover, our previous findings on HBV-related and HCV-related HCC showed no miR-27a upregulation compared with the level in the paired background liver (1.14-fold, $P = 0.49$).

In summary, we have revealed the important role of miR-27a in HCV replication for the first time. These findings will be applicable in the improvement of the therapeutic effects of anti-HCV therapy, especially in patients showing treatment resistance and severe hepatic steatosis.

REFERENCES

1. Esteller M. 2011. Non-coding RNAs in human disease. Nat. Rev. Genet. **12**:861–874.
2. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. 2009. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology **49**:1098–1112.
3. André P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Brechot C, Paranhos-Baccala G, Lotteau V. 2002. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. **76**:6919–6928.
4. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. 1992. Association of hepatitis C virus in human sera with beta-lipoprotein. Med. Microbiol. Immunol. **181**:293–300.
5. Thomssen R, Bonk S, Thiele A. 1993. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med. Microbiol. Immunol. **182**:329–334.
6. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. 1999. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. **96**:12766–12771.
7. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. 2002. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J. Med. Virol. **68**:206–215.
8. Triyatni M, Saunier B, Maruvada P, Davis AR, Ulianich L, Heller T, Patel A, Kohn LD, Liang TJ. 2002. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J. Virol. **76**:9335–9344.
9. Shi ST, Lee KJ, Aizaki H, Hwang SB, Lai MM. 2003. Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J. Virol. **77**:4160–4168.
10. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. **9**:1089–1097.
11. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr, Ye J. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very-low-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. **104**:5848–5853.
12. Bressler BL, Guindi M, Tomlinson G, Heathcote J. 2003. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology **38**:639–644.
13. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. 2003. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology **38**:75–85.

14. **Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P.** 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science **309:**1577–1581.

15. **Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K.** 2009. Regulation of the hepatitis C virus genome replication by miR-199a. J. Hepatol. **50:**453–460.

16. **Hou W, Tian Q, Zheng J, Bonkovsky HL.** 2010. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology **51:**1494–1504.

17. **Bandyopadhyay S, Friedman RC, Marquez RT, Keck K, Kong B, Icardi MS, Brown KE, Burge CB, Schmidt WN, Wang Y, McCaffrey AP.** 2011. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J. Infect. Dis. **203:**1753–1762.

18. **Cheng JC, Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, Huang HD.** 2012. Let-7b is a novel regulator of hepatitis C virus replication. Cell. Mol. Life Sci. **69:**2621–2633.

19. **Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB.** 2012. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J. Virol. **86:**10221–10225.

20. **Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ.** 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. **11:**791–796.

21. **Shetty S, Kim S, Shimakami T, Lemon SM, Mihailescu MR.** 2010. Hepatitis C virus genomic RNA dimerization is mediated via a kissing complex intermediate. RNA. **16:**913–925.

22. **Che ML, Yan YC, Zhang Y, Gu Y, Wang NS, Chen N, Mao PJ, Zhang JY, Ding XQ, Yuan WJ, Mei CL, Yao J, Fan YL, Zhou Y, Zhang W, Zhu HW, Liu M, Jin HM, Qian JQ.** 2009. Analysis of drug-induced acute renal failure in Shanghai. Zhonghua Yi Xue Za Zhi **89:**744–749. (In Chinese.)

23. **Shimakami T, Welsch C, Yamane D, McGivern DR, Yi M, Zeuzem S, Lemon SM.** 2011. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology **140:**667–675.

24. **Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM.** 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. **103:**2310–2315.

25. **Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S.** 2011. Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. Gastroenterology **141:**128–140.

26. **Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ.** 2007. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut **56:**1124–1131.

27. **Honda M, Nakamura M, Tateno M, Sakai A, Shimakami T, Shirasaki T, Yamashita T, Arai K, Sakai Y, Kaneko S.** 2010. Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C. J. Hepatol. **53:**817–826.

28. **Shirasaki T, Honda M, Mizuno H, Shimakami T, Okada H, Sakai Y, Murakami S, Wakita T, Kaneko S.** 2010. La protein required for internal ribosome entry site-directed translation is a potential therapeutic target for hepatitis C virus replication. J. Infect. Dis. **202:**75–85.

29. **Chung S, Gebre AK, Seo J, Shelness GS, Parks JS.** 2010. A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulation of hepatic VLDL triglyceride secretion. J. Lipid Res. **51:**729–742.

30. **Lewis BP, Burge CB, Bartel DP.** 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell **120:**15–20.

31. **Lee JS, Mendez R, Heng HH, Yang ZQ, Zhang K.** 2012. Pharmacological ER stress promotes hepatic lipogenesis and lipid droplet formation. Am. J. Transl. Res. **4:**102–113.

32. **Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S.** 2009. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett. **583:**759–766.

33. **Kim SY, Kim AY, Lee HW, Son YH, Lee GY, Lee JW, Lee YS, Kim JB.** 2010. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression. Biochem. Biophys. Res. Commun. **392:**323–328.

34. **Schmitz G, Langmann T.** 2005. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim. Biophys. Acta **1735:**1–19.

35. **Liu M, Chung S, Shelness GS, Parks JS.** 2012. Hepatic ABCA1 and VLDL triglyceride production. Biochim. Biophys. Acta **1821:**770–777.

36. **Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K.** 2010. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J. Virol. **84:**12048–12057.

37. **Mancone C, Steindler C, Santangelo L, Simonte G, Vlassi C, Longo MA, D'Offizi G, Di Giacomo C, Pucillo LP, Amicone L, Tripodi M, Alonzi T.** 2011. Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins. Gut **60:**378–386.

38. **Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN.** 2004. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. **23:**4051–4060.

39. **O'Brien TR.** 2009. Interferon-alfa, interferon-lambda and hepatitis C. Nat. Genet. **41:**1048–1050.

40. **Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J.** 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. **41:**1100–1104.

41. **Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M.** 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. **41:**1105–1109.

42. **Chung S, Timmins JM, Duong M, Degirolamo C, Rong S, Sawyer JK, Singaraja RR, Hayden MR, Maeda N, Rudel LL, Shelness GS, Parks JS.** 2010. Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism. J. Biol. Chem. **285:**12197–12209.

43. **Porse BT, Pedersen TA, Xu X, Lindberg B, Wewer UM, Friis-Hansen L, Nerlov C.** 2001. E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo. Cell **107:**247–258.

44. **Libri V, Helwak A, Miesen P, Santhakumar D, Borger JG, Kudla G, Grey F, Tollervey D, Buck AH.** 2012. Murine cytomegalovirus encodes a miR-27 inhibitor disguised as a target. Proc. Natl. Acad. Sci. U. S. A. **109:**279–284.

45. **Marcinowski L, Tanguy M, Krmpotic A, Radle B, Lisnic VJ, Tuddenham L, Chane-Woon-Ming B, Ruzsics Z, Erhard F, Benkartek C, Babic M, Zimmer R, Trgovcich J, Koszinowski UH, Jonjic S, Pfeffer S, Dolken L.** 2012. Degradation of cellular mir-27 by a novel, highly abundant viral transcript is important for efficient virus replication in vivo. PLoS Pathog. **8:**e1002510. doi:10.1371/journal.ppat.1002510.

46. **Cazalla D, Yario T, Steitz JA.** 2010. Down-regulation of a host microRNA by a Herpesvirus saimiri noncoding RNA. Science **328:**1563–1566.

47. **Chhabra R, Dubey R, Saini N.** 2010. Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol. Cancer **9:**232.

48. **Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, Yao X, Pan Z, Zhang P, Li J, Wan D, Gu J.** 2008. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int. J. Cancer **123:**972–978.

49. **Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT.** 2012. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis **33:**1113–1120.